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ABSTRACT
Mixed cryoglobulinemia (MC), is a HCV-related, clinically benign, 
lymphoproliferative disorder (LPD) that may evolve into a non Hodgkin’s lymphoma 
(NHL). Significant associations were found between two single nucleotide 
polymorphisms near NOTCH4 (rs2071286) and the HLA class II (rs9461776) genes 
and HCV-related MC syndrome (MCS). We analyzed NOTCH4 rs2071286 and HLA-II 
rs9461776 in 3 HCV-related LPD groups (asymptomatic MC, MCS, NHL) with HCV 
infection without lymphoproliferative disorders.
We found a positive relationship between NOTCH4 rs207186 T minor 
allele frequency (MAF) and patients with HCV-related LPDs at risk of NHL (Chi-square 
test for trend = 14.84 p = 0.0001), in accordance with an over-dominant model in the 
NHL group (CT vs CC + TT, OR=1.88, 95% CI 1.24–2.83, p = 0.0026).
Regarding HLA II rs9461776, G MAF increased in patients with HCV-
related LPDs at risk of NHL (Chi-square test for trend = 8.40 p = 0.0038), in accordance 
with a recessive genotypic model in the NHL group (G/G vs A/A + A/G, OR = 11.07, 
95% CI 2.37–51.64, p = 0.0022).
Both NOTCH4 rs2071286 and HLA-II rs9461776 were present on chromosome 6 
and showed D’ and r values of linkage disequilibrium (LD) of about 0.5 values, thereby 
suggesting there is no extensive LD in the HCV+ population.
This data shows that the previously demonstrated association between NOTCH4 
rs2071286 and HLA-II rs9461776 polymorphisms and HCV-related MCS could be 
extended to overall patients with HCV-related LPDs. The significant relationship 
between rs2071286 and rs9461776 MAF and the increased risk for NHL, suggests 
their use as non-invasive markers to categorize patients at risk of lymphoma.
INTRODUCTION
Hepatitis C Virus (HCV) has a high propensity to 
persist in the host, leading to chronic liver disease but 
it is also known that in a smaller percentage of patients 
it can cause lymphoproliferative disorders (LPDs) [1]: 
the most frequent one is called mixed cryoglobulinemia 
(MC) [2, 3]. MC is a lymphoproliferative/autoimmune 
disease, clinically benign, with an increased risk of 
developing B cell Non-Hodgkin lymphoma (NHL) 
[1, 4, 5]. MC is characterized by the presence of 
circulating immune-complexes called cryoglobulins 
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(CGs). Some patients exhibit a symptomatic MC called 
MC syndrome (MCS) or MC Vasculitis which derives 
from a systemic involvement of small, medium-sized 
vessels; other subjects do not show any symptoms even 
if they have CGs in their serum. The relationship between 
NHL and HCV has now been confirmed in a large number 
of studies with the most convincing evidence resulting 
from the reduced incidence of NHL in patients after 
successful HCV eradication [6] and by using different 
transgenic murine models [7, 8]. However, the lymphoma 
genetic mechanism related to HCV infection still has to 
be clarified. Several models have been proposed not all 
mutually exclusive, such as a direct oncogenic effect or 
an antigen driven lymphocyte proliferation [1, 9–11]. 
A rational hypothesis could be a specific favorable 
host’s genetics that increases the susceptibility to LPDs 
when the virus persists. While there was not clear and 
convincing evidence to sustain a role of particular HCV 
genotypes, the differing prevalence of HCV-related LPDs 
in different geographical areas [12] seems to confirm the 
importance of host genetics predisposed to LPDs [13–17]. 
Several genetic studies had focused their attention on the 
human leukocyte antigen (HLA) variants highlighting 
an association between specific classes of genes and the 
susceptibility to the development of HCV-related MC and 
NHL [18–22]. However a clear result as of today has not 
been obtained, due in part to the extreme polymorphic 
nature of the HLA loci. A multicenter Genome Wide 
Association Study (GWAS) showed an association of 
two particular polymorphisms located on chromosome 
6 with HCV-related MC Vasculitis compared to HCV 
controls without LPDs [23]; the first one is a single 
nucleotide polymorphism (SNP) (rs2071286) located 
in an intronic region of the NOTCH4 gene, the second 
one is a SNP (rs9461776) located between HLA-DRB1 
and HLA-DQA1 gene segments of the class II major 
histocompatibility complex (MHC). 
NOTCH4 gene encodes for a protein belonging 
to the NOTCH family of transmembrane proteins with 
repeated extracellular epidermal growth factor-like 
domains and an intracellular domain [24, 25]. NOTCH 
signaling is involved in many biological processes, ranging 
from embryonic development to cell proliferation and 
survival and its main action is to regulate the interaction 
between adjacent cells through binding with its cognate 
ligand [26]. Notch4 is expressed in blood and human 
bone marrow cells –derived CD34+ progenitor cells as 
well as in CD34− cell population [27]. It was suggested 
that activation of NOTCH4 leads to enhanced stem cell 
activity, reduces differentiation and alters lymphocyte 
development [28].
Based on the GWAS results, we evaluated the 
allelic frequencies of the NOTCH4 rs2071286 and the 
HLA-II rs9461776 SNPs, in a wide cohort of patients 
with different HCV-related LPDs with circulating 
cryoglobulins, with and without vasculitis, or with HCV− 
related NHL, comparing them to a group of HCV+ 
patients without LPDs.
RESULTS 
Patient characteristics and group distribution
Patient characteristics and group distribution were 
shown in Table 1. 
The groups did not significantly differ in terms of 
viremia titers or viral genotype distribution, whereas, 
as expected, the female sex was more significantly 
represented in the MCS-HCV group (p < 0.01) and NHL-
HCV group (p < 0.05). 
Genotype frequencies
Results obtained from the analysis of allele and 
genotype, for NOTCH4 rs2071286 and HLA-II rs9461776 
are summarized in Figure 1 and Figure 2 (allele frequency 
in panels A and genotype frequency in panels B).
NOTCH4 rs2071286 SNP analysis
 all the three groups of patients with HCV-related 
LPDs considered in this study (MC-HCV, MCS-HCV and 
NHL-HCV) showed a higher presence of the rs2071286 
T minor allele frequency (MAF) in respect to the HCV 
control group (OR 1.79, 95% CI 1.04–3.08, p = 0.04; OR 
2.59, 95% CI 1.57–4.26, p = 0.0002 and OR 2.6, 95% CI 
1.5–4.5, p = 0.0006, respectively) (Figure 1, panel 1A). 
We found a positive relationship between T minor 
allele frequency (MAF) and the proportion of patients 
with HCV-related LPDs at risk of NHL (chi-square test 
for trend = 14.84, p = 0.0001), in accordance with an over-
dominant model in NHL group (CT vs CC + TT, 
OR = 1.88, 95% CI 1.24–2.83, p = 0.0026).
HLA rs9461776 SNP analysis 
Regarding the HLA-II rs9461776 polymorphism, 
we found a G MAF increase in the proportion of patients 
with HCV-related LPDs at risk of NHL (chi-square 
test for trend = 8.40 p = 0.0038) (Figure 2, panel A), 
in accordance with a recessive genotypic model in 
the NHL group (G/G vs A/A + A/G, OR = 12, 95% CI 
2.50–57.51, p = 0.0006).
Linkage disequilibrium
To date, the functional role of NOTCH4 rs2071286 
and HLA-II rs9461776 are unknown. In particular, it is 
unknown whether rs168924 or HLA-II rs9461776 are in 
linkage disequilibrium (LD) with another functionally 
significant SNP. Linkage disequilibrium between NOTCH4 
rs2071286 and HLA-II rs9461776 polymorphisms was 
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then calculated. Genotyping of our samples indicated 
no significant LD between the 2 SNPs (D’ = 0.5423, r 
= 0.5184), therefore NOTCH4 rs2071286 and HLA-II 
rs9461776 did not usually occur on the same haplotype.
Haplotype analysis
The two SNPs have been grouped into 4 haplotypes 
(Table 2). The more frequent haplotype AC included 
2 wild type alleles HLA-II A-rs9461776 and NOTCH4 
C-rs2071286.
The remaining haplotypes that all included at least 
one minor allele (GT, AT, and GC) were found associated 
with the NHL-HCV group of patients (OR. 3.81, 
p = 0.001,; OR. 3.63, p = 0.005,; OR 6.85, p = 0.00007, 
respectively). The most frequent haplotype (22.8%) 
associated with NHL-HCV included both the GT MAF, 
while the GC haplotype showed the highest OR value 
Table 1: Main clinical and laboratory findings of HCV chronically infected patients according to 
extra-hepatic conditions
HCV
(n = 85)
MC-HCV
(n = 73)
MCS-HCV
(n = 108)
NHL-HCV
(n = 61)
Mean Age (years) 52.4 ± 11.6 56.2 ± 12.5 61.5 ± 13.9 62.6 ± 7.6
Sex (male/female) 48/37 38/35 40/68§ 23/38§§
Viral titer (IU/mL × 106) 2.9 ± 3.1 3.3 ± 2.8 3.4 ± 6.6 3.5 ± 4.1
HCV genotype
1
2
3–4
47 (55%)
24 (28%)
14 (17%)
41 (56%)
17 (23%)
15 (21%)
60 (55%)
32 (30%)
16 (15%)
52 (85%)
7 (12%)
2 (3%)
Mean cryocrit (%) - 3.4 ± 5.1 11.7 ± 17.1 4.8 ± 5.4
*
Histology
Diffuse Large Cell Lymphoma
Marginal Zone Lymphoma
Follicular Lymphoma
Small Lymphocytic Lymphoma
MALT
Burkitt lymphoma
26 (43%)
25 (41%)
4 (6.5%)
3 (5%)
2 (3%)
1 (1.5%)
MC: Mixed Cryoglobulinemia; MCS: Mixed Cryoglobulinemia Syndrome; NHL: Non-Hodgkin’s Lymphoma; IU: 
International Units; MALT: mucosa-associated lymphoid tissue;
*data were available for 33 patients out of the 61 analyzed; §p < 0.01; §§p < 0.05.
Figure 1: (Panel A) NOTCH4 rs2071286 allele frequency; *p = 0.004; **p = 0.0002; ***p = 0.0006; (Panel B) NOTCH4 rs2071286 
genotype frequency; °p = 0.008; °°p = 0.0122; °°°p = 0.006.
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(6.85) denoted HLA-II G MAF may be more strongly 
associated than NOTCH4 C-rs2071286 with NHL-
HCV condition. By converse, NOTCH4 T-rs2071286 
showed the best association with MCS-HCV cases, since 
both GT and AT haplotypes found were significantly 
associated with MCS-HCV (p = 0.003, O.R. 2.54 and 
p = 0.002, O.R. 2.29, respectively) (Table 2).
DISCUSSION
Two SNPs, previously associated with symptomatic 
MC in a multicenter GWAS study were tested. By using 
these SNPs we were able to define a trend for an increased 
risk for NHL-HCV development in patients with HCV-
related LPDs. Since the Therapy Guidelines for HCV-
treatment with direct acting antiviral drugs (DAAs) are 
stringent (http://www.easl.eu/medias/cpg/HCV2016/
English-report.pdf), an easy way to recognize subjects at risk 
of NHL may be helpful to evaluate the treatment priority.  
The HLA region is well known for being associated 
with different autoimmune and infectious diseases [29, 30]. 
Both the SNPs tested in the present study lie in 
non-coding regions, suggesting that SNPs had either 
a regulatory role or were indirect tag-SNPs useful to 
identifying functional and until today unknown mutations 
involved in the HCV-related LPDs process. The medium 
LD between NOTCH4 rs2071286 and HLA-II rs9461776 
polymorphisms suggested that a functional sequence 
included in the NOTCH4 and HLA-II region, could have 
a role in HCV-related LPDs. A potential role of NOTCH4 
in the pathogenesis of HCV-related LPDs and members 
of the NOTCH family in several malignancies such as 
leukemia, gastric breast, bladder, ovarian and colon cancer 
were consistent with a role of NOTCH protein alteration, 
in the onset of some autoimmune disorders including 
NHL-HCV malignancies [31–34]. Moreover, Arcaini 
and co-workers observed that NOTCH pathway somatic 
mutations are associated with 25% of HCV-positive 
diffuse large B-cells lymphoma cases [35].  
Among the notch family, NOTCH4 and its signaling 
is the least studied member; as already mentioned, several 
reports showed an association between SNPs either 
within or near NOTCH4 and different autoimmunities 
[36], but, so far, no indication about its functional role 
has been proposed. In fact, its expression seems to be 
relevant for the development of the central nervous system 
[37] and vascular system [38], and also appears to play 
a role in the differentiation of naive CD4+ T cells [39]. 
Interestingly, a very recent paper listed NOTCH4 among 
genes with a pleiotropic effect, meaning that it could be 
able to determine multiple phenotypic traits [40]. As other 
examples of pleiotropy, NOTCH4 variants could determine 
a shared genetic susceptibility mechanism between 
different diseases or physiological processes. in this light, 
Figure 2: (Panel A) HLA-II rs9461776  allele frequency; *p = 0.0015; (Panel B) HLA-II rs9461776  genotype frequency; °p = 0.0006. 
Table 2: NOTCH4 rs2071286 and HLA rs9461776 haplotype 
Haplotype HCV %
MC-HCV
%
OR (95% CI) CRUDE
MCS-HCV
%
OR (95% CI)  CRUDE
NHL-HCV
%
OR (95% CI)  CRUDE
Overall p Overall p Overall p
AC
GT
AT
GC
75.99
11.41
8.03
4.56
65.07
15.79
13.5
5.64
1 (reference)
1.65 (0.77–3.52)
1.90 (0.82–4.41)
1.37 (0.43–4.39)
 
0.16
0.10
0.55
55.69
20.76
17.7
5.85
1 (reference)
2.54 (1.30–5.01)
2.29 (1.39–6.26)
1.58 (0.55–4.64)
 
0.003
0.002
0.35
41.15
22.82
17.18
18.85
1 (reference)
3.81 (1.52–9.59)
3.63 (1.28–10.32)
6.85 (2.18–22.10)
  
0.001
0.005
0.00007
MC: Mixed Cryoglobulinemia; MCS: Mixed Cryoglobulinemia Syndrome; NHL: Non-Hodgkin’s Lymphoma; OR: Odds ratio; CI: confidence interval; statistical analysis was 
performed using X2 test.
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it is not surprising that a gene, so far implied in the biology 
of development, could also be involved in the development 
of autoimmunities and haematological malignancies. 
Our data also suggested that HLA-II region 
represented a strong susceptibility area for several HCV-
related LPDs, in accordance with previous studies [41, 42].
In conclusion, the present study not only confirmed 
the association of NOTCH4 rs2071286 and HLA-II 
rs9461776 with HCV-MCS, but indicated these SNPs as 
potential markers for HCV-related LPDs susceptibility, 
in particular with an increased risk for HCV-NHL 
development. These observations should be confirmed in a 
wider population before suggesting the use of this SNP as 
a biomarker at a higher risk of developing hematological 
malignancies. 
Nonetheless, together with the evidence of 
previously published results regarding these SNPs in 
HCV-related disorders, our study highlights the interest 
for a deeper molecular analysis aimed at clarifying the 
functional role of genes included among NOTCH4 and the 
HLA-II region gene that increases the odds of developing 
a NHL during HCV-chronic infection.
MATERIALS AND METHODS
This is a retrospective case-control study; patients 
were recruited from April 2009 to January 2016 in 
three different Italian Centers: Center for Systemic 
Manifestations of Hepatitis Viruses (MaSVE) (Department 
of Experimental and Clinical Medicine, University of 
Florence, Florence); Centro di Riferimento Oncologico, 
National Cancer Institute, Aviano, Italy and the 
Department of Biomedical and Biotechnological Sciences, 
University of Catania, Italy.
Peripheral blood samples from 327 HCV-infected 
patients, grouped as follows: 85 patients without any 
evidence of serum cryoglobulins (CGs) or autoimmune/
lymphoproliferative disorders (HCV group), 73 with 
circulating CGs but without symptoms of vasculitis (MC-
HCV group), 108 with HCV-related CGs and vasculitis 
(MCS-HCV) and 61 with HCV-related NHL (NHL-HCV) 
were analyzed.
The ethnicity of all the patients was Caucasian. 
Patients positive at the HBV and/or the HIV test were 
excluded from the study. Demographic and clinical 
characteristics of each groups are reported on Table 1.
HCV infection was proven by detecting circulating 
anti-HCV antibodies (EIA-2 and RIBA-2; Ortho 
Diagnostic Systems, Raritan, NJ) and HCV RNA 
(AMPLICOR HCV Test, v2.0; Roche Diagnostics, 
Alameda, CA). The HCV genotype was assessed by the 
VERSANT HCV Genotype 2.0 assay (Siemens Healthcare 
Diagnostics, Deerfield, IL).
Mixed cryoglobulinemia was assessed by circulating 
CGs found in at least three metachronous samples. All 
patients with MCS satisfied available classification criteria. 
[43, 44]. NHL type was defined according to updated 
WHO classification of hematological malignancies [45].
The study was conducted in accordance with the 
ethical guidelines of the Helsinki Declaration. All subjects 
provided written informed consent and the protocol was 
approved by independent local ethics committees.
Cell isolation and DNA extraction 
Peripheral blood mononuclear cells (PBMCs) were 
isolated from fresh anticoagulated blood by gradient 
precipitation on Lymphoprep (Axis-Shield PoC AS, Oslo, 
Norway) according to the manufacturer’s instructions. 
After the second wash, the cells were counted and stored 
at −80°C. 
Genomic DNA was extracted from PBMCs using 
an QIAamp DNA Mini Kit (QIAGEN Inc, Valencia, CA, 
USA) or from whole blood samples using a Nucleospin 
Blood Kit (Macherey-Nagel GmbH & Co. KG, Düren, 
Germany) according to the manufacturer’s instructions.
SNPs genotyping
The rs2071286 (NOTCH4) and the rs9461776 
(HLA) SNP genotyping was performed using a specific 
TaqMan SNP Genotyping Assay (Applied Biosystem, 
Foster City, CA, USA) with supplied probes and primers, 
on a Rotor Gene 6000 (Corbett Research, Sidney, 
Australia). 
Statistical analysis
Statistical analysis was performed using SPSS 
statistical software, version 23 (SPSS, Inc. Chicago, IL, 
USA). Comparisons of genotype and allele frequencies 
were performed using the X2 test. The haplotypes 
frequencies were estimated using PowerMarker software, 
version 3.25 (http://statgen.ncsu.edu/powermarker/), and 
the obtained data was arranged in a contingency table. 
Comparisons of haplotype frequencies were performed 
using the X2 test without confounding variables. Linkage 
disequilibrium between SNPs was analyzed using 
PowerMarker software, version 3.25 as well. All tests 
were two-sided at a 0.05 significance level.
Abbreviations
mixed cryoglobulinemia: MC; non-Hodgkin’s 
lymphoma NHL; lymphoproliferative disorder LPD; 
mixed cryoglobulinemia syndrome MCS; genome wide 
association study: GWAS; minor allele frequency: MAF; 
human leukocyte antigen: HLA; cryoglobulins: CGs; 
linkage disequilibrium: LD; peripheral blood mononuclear 
cells: PBMCs. 
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